GNTA · Genenta Science SpA ADR
-
-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US36870W1009 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 15M |
|---|---|
| PE Ratio | None |
| Target Price | 6.9801 |
| Beta | 0.73 |
| Dividend Yield | None |
ABOUT
Genenta Science SpA ADR
Genenta Science S.p.A., a clinical-stage biotechnology company, develops hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company offers Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is developing Temferon for use in the treatment of other solid tumor indications. In addition, the company develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
Learn More